No attachments available.
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury
Contact and place of performance
fred Ettehadieh
GBR
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer's disease and mild to moderate traumatic brain injury. IDIQ Contract No. 75N95024D00002 IDIQ Contract Award Dollar Amount: $962,486.00 Minimum Order; $1,988,692.00 Maximum Order Limitation
The National Institutes of Health NIDA awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for the clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation. The scope of this work involves research related to early mild Alzheimer’s disease and mild to moderate traumatic brain injury. This requirement is classified under NAICS 541990 All Other Professional, Scientific, and Technical Services and PSC B504 SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL.
Performance of the clinical evaluation services occurs in the United Kingdom. The IDIQ contract, designated as 75N95024D00002, was awarded following solicitation 75N95022R00041. The financial structure of the award includes a minimum order value of $962,486.00 and a maximum order limitation of $1,988,692.00. The award notice was finalized and published on January 31, 2024.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.